Italia markets close in 3 hours 48 minutes

Esperion Therapeutics, Inc. (ESPR)

NasdaqGM - NasdaqGM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,0900+0,1800 (+9,42%)
Alla chiusura: 04:00PM EDT
2,1800 +0,09 (+4,31%)
Preborsa: 04:35AM EDT
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente1,9100
Aperto1,9300
Denaro2,0700 x 11300
Lettera2,1000 x 3800
Min-Max giorno1,9297 - 2,1250
Intervallo di 52 settimane0,7000 - 3,4000
Volume4.928.175
Media Volume6.235.896
Capitalizzazione395,848M
Beta (5 anni mensile)0,82
Rapporto PE (ttm)N/D
EPS (ttm)-2,0300
Prossima data utili07 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A7,41
  • GlobeNewswire

    American College of Cardiology Program to Increase Cholesterol Screenings

    Quality Improvement and Education Program sponsored by Amgen, Esperion to improve adherence to guideline recommendations for managing LDL WASHINGTON, Sept. 12, 2023 (GLOBE NEWSWIRE) -- The American College of Cardiology, through a strategic collaboration with Amgen and Esperion, is launching a new quality improvement campaign, “Driving Urgency in LDL Screening,” to increase the rate of diagnostic LDL screening in patients without a prior cardiac event as well as those with known cardiovascular d

  • GlobeNewswire

    Esperion to Participate in H.C. Wainwright 25th Annual Global Investment Conference

    ANN ARBOR, Mich., Aug. 28, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced its participation in the H.C. Wainwright 25th Annual Global Investment Conference. Sheldon Koenig, President and Chief Executive Officer, will participate in a corporate presentation on Monday, September 11, 2023 at 3:00 PM ET. The Esperion management team will also host investor meetings that same day. To register for the live webcast, follow this link. A live audio webcast can be accessed on the investo

  • GlobeNewswire

    Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

    – In total cardiovascular event analysis, bempedoic acid shows 20% risk reduction in MACE-4 and 17% risk reduction in MACE-3 – – In an analysis of patients with diabetes, bempedoic acid shows 17% risk reduction in MACE-4 and 20% risk reduction in MACE-3 – – No increase in development of new onset diabetes in patients randomized to bempedoic acid compared to placebo – ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two o